Effect of N-acetylcysteine on COVID-19 treatment
Phase 3
- Conditions
- COVID-19 (SARS-CoV-2 infection)Infections and Infestations
- Registration Number
- ISRCTN60069084
- Lead Sponsor
- King Saud Medical City
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 1180
Inclusion Criteria
1. Adults (above 18 years)
2. Admitted to the hospital
3. Confirmed COVID-19 patient by RT-PCR test from any specimen (nasal, throat swab, sputum, etc)
4. On oxygen supplement ( Category 4, 5, 6, 7 on the ordinal scale)
Exclusion Criteria
1. Active indication and use of NAC
2. Known allergy to NAC
3. In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of provision of treatment e.g. patients on ECMO at time of randomization
4. Patients enrolled in other investigational drug studies are not eligible for our study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> Time to recovery: day of recovery is defined as the first day on which one of the following three categories from the Ordinal scale on clinical improvement per WHO blueprint in COVID-19 therapeutic trials:<br> 1. Hospitalized, not requiring supplemental oxygen<br> 2. Not hospitalized, limitation on activities and/or requiring home oxygen<br> 3. Not hospitalized, no limitations on activities<br> Measured using patient’s medical records until discharge<br>
- Secondary Outcome Measures
Name Time Method